Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season

Chao Jiang a, b, 1, Xingang Yao c, 1, Yulin Zhao a, 1, Jianmin Wu a, Pan Huang a, Chunhua Pan d, **, Shuwen Liu c, ***, Chungen Pan a, ***

a Laboratory of Molecular Virology & Immunology, Technology Innovation Center, Haid Research Institute, Guangdong Haid Group Co., Ltd, Guangzhou, 511400, China
b School of Life Sciences, Bengbu Medical College, Bengbu, Anhui, 233030, China
c State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China
d Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, 510000, China

ABSTRACT

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to sweep the world, causing infection of millions and death of hundreds of thousands. The respiratory disease that it caused, COVID-19 (stands for coronavirus disease in 2019), has similar clinical symptoms with other two CoV diseases, severe acute respiratory syndrome and Middle East respiratory syndrome (SARS and MERS), of which causative viruses are SARS-CoV and MERS-CoV, respectively. These three CoVs resulting diseases also share many clinical symptoms with other respiratory diseases caused by influenza A viruses (IAVs). Since both CoVs and IAVs are general pathogens responsible for seasonal cold, in the next few months, during the changing of seasons, clinicians and public health may have to distinguish COVID-19 pneumonia from other kinds of viral pneumonia. This is a discussion and comparison of the virus structures, transmission characteristics, clinical symptoms, diagnosis, pathological changes, treatment and prevention of the two kinds of viruses, CoVs and IAVs. It hopes to provide information for practitioners in the medical field during the epidemic season.

In December 2019, a novel coronavirus, SARS-CoV-2, caused a pneumonia epidemic in Wuhan, Hubei province of China. It erupted in many other countries in the following months and eventually became a worldwide pandemic. The pneumonia was officially named COVID-19 by World Health Organization (WHO) [1]. So far, the pandemic is still accelerating. More than 4.3 million people were confirmed infected, 290,000 more people died globally [2], and the virus transmission is expected to last for more than one year [3]. At the same time, other types of coronaviruses and influenza viruses, which have been widespread in the world, may invade human society again during this winter or in other circumstances, circulating together with the SARS-CoV-2 and causing more serious respiratory diseases [4,5]. It is necessary to investigate whether the simultaneous prevalence of SARS-CoV-2 and other respiratory viruses, such as IAVs, can promote the spreading of each other. In addition, because the clinical symptoms caused by CoVs and IAVs infection are very similar to each other [6], it will bring further challenges to clinicians in the timely diagnosis and treatment of patients. This article will summarize and compare the epidemic characteristics, clinical symptoms, treatment, and prevention measures for the diseases which are caused by CoVs or IAVs respectively, hoping to provide a brief comparative information for the clinicians and researchers who are working in the related fields.
1. Viruses

CoVs are enveloped, single strand positive-sense RNA viruses with a genome consisting of 26 to 32k nucleotides, expressing 16 nonstructural proteins (nsP1 to nsP16) and four structural proteins, such as spike (S protein), membrane, envelope, and nucleocapsid proteins [7]. As shown in Fig. 1A, S protein is located on the surface of virus particles, which plays a key role in virus entry into host cells, and is also one of the major targets of antiviral drugs and neutralizing antibodies [8–11]. CoVs are divided into four genera which belongs to Coronaviridae, alpha, beta, delta and gamma CoVs. So far, there are seven CoVs causing human diseases, including three highly pathogenic CoVs (HPCoVs) (SARS-CoV-2, MERS-CoV, and SARS-CoV) and four normal human CoVs (abbreviated as HCoVs) (HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1) [12]. HCoV-229E and HCoV-NL63 belong to the alpha genus, while the other 5 CoVs belong to the beta genus. The genes of S protein from the three HPCoVs form 3 clusters, as shown in the polygenetic tree in Fig. 1A. Compared with MERS-CoV, the S protein gene of SARS-CoV-2 is a little bit closer to SARS-CoV, as reported in Fig. 1A. Compared with MERS-CoV, the S protein gene of SARS-CoV-2 is a little bit closer to SARS-CoV, as reported in Fig. 1A.

CoVs replication usually occurs in the cytoplasm. As show in Fig. 1B, virus binds to its receptor angiotensin converting enzyme 2 (ACE2) (SARS-CoV-2, SARS-CoV, and HCoV-NL63), dipeptidyl peptidase-4 (DPP4) (MERS-CoV), 9–O-Acetylated sialic acid (HCoV-OC43), or human aminopeptidase N (CD13) (HCoV-229E) [18], and entry into the cell by direct membrane fusion or endocytosis, in which the virus membrane fusing with cell membrane or endosome membrane and releasing viral RNA, then the virus positive-sense RNA was used as a template to synthesize negative-sense genomic RNA, this was template again to transcript mRNAs and also to replicate progeny positive-sense RNA. Viral proteins were translated by mRNAs through the endoplasmic reticulum and Golgi apparatus system for packaging into mature viral particles with the progeny RNA in the cytoplasm. Then the virions was transported to cell membrane and released by exocytosis [7,15].

Similar to CoV, IAV is also an enveloped virus, with genome of a single strand but negative-sense RNA, which is divided into eight segments, encoding 12 proteins, including PB2, PB1, PB1–F2, PB1 N40, PA, NP, HA, NA, M1, M2, NS, and NEP/NE2, respectively [16]. As shown in Fig. 1C, haemagglutinin (HA) and neuraminidase (NA) are distributed on the surface of virus particles, which is the basis for subtype classification of IAVs and also play important roles during the process of virus invasion and mature virus releasing [17,18]. Like S protein of CoVs, HA and NA are very important targets of antiviral drugs and vaccines [19–21]. In recent 30 years, three subtypes of IAVs, including H1N1 pdm09 virus causing 2009 flu pandemic [22], and two highly pathogenic avian viruses, H5N1 and H7N9 viruses, had caused severe respiratory diseases and resulted in thousands of deaths or high mortality in humans [23,24]. The majority subtype of seasonal IAVs is H3N2 [25]. The polygenetic tree in Fig. 1C displays the three clusters of HA genes. They show a distinct difference from each other, with the HA gene of H5N1 virus generating more mutations during its transmission as reported [26].

Compared to CoV, there are two major differences in the life cycle of IAV. First, the IAV needs to replicate its genome in the nucleus. Secondly, the virions are released by assembly and budding from cellular membrane. As illustrated in Fig. 1D, IAV binds to receptor s,2,3-linked sialic acid (H7N9 and H5N1) or s,2,6-linked sialic acid (H1N1 and H3N2) to form endosome and enters into cell, and the viral RNA was released into the cytoplasm by viral-endosome membrane fusion. Then the viral RNA is imported into the nucleus, and once there starts both virus RNA transcription and replication. After mRNAs and progeny negative-sense RNAs are exported to cytoplasm, the proteins are translated and trafficked to the cell membrane into packaged RNAs. The mature virus then buds from the cells [27].

2. Transmission

For the spread of viruses, there are no borders between countries as more and more interactions and cooperation were established worldwide. Since the CoVs and IAVs were identified as the major pathogens for respiratory diseases in last century, they have traveled to many corners of the world [28,29]. The transmission and infectivity related information of these viruses were summarized in Table 1. There are two seasonal flu viruses included, HCoVs and H3N2 IAV (HCoVs represents four CoVs that cause seasonal cold, HCoV229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1, for convenience in following discussion, they will be denoted as one CoV in this article.). They usually cause moderate clinical symptoms and spread globally [28,30]. The rest of six viruses either show high pathogenicity or are highly transmissible, which could cause much danger for human society. These viruses are called here as HPHTs, which stands for high pathogenicity or highly transmissible viruses. Of the HPHTs, the spread of SARS-CoV-2 is accelerated due to its ability to transmit through airborne droplets during the incubation period [31]. That it may also transmit between human and animals becomes another challenge in the control of the pandemic [31]. Another two viruses, MERS-CoV and SARS-CoV, reported in 2012 and 2003 respectively, caused mortalities of 35% and 9% in patients respectively. Their transmission mostly started after the patients started showing clinical symptoms [15,32]. Therefore, they could not travel in humans too long before being discovered and controlled. All ages of people were susceptible to these 3 CoVs, but senior people were more likely to be infected with SARS-CoV-2 and develop more severe clinical symptoms, while mostly younger people were infected with SARS-CoV [33,34].

Some subtypes of IAVs also resulted in pandemic and caused large number of death tolls. Besides the well documented Spanish flu in 1918, H1N1 pdm09 virus spread to 214 countries one year after it appeared in USA in 2009 [35]. It was noticed that the virus caused more deaths in people who are younger than 65 [36]. Some scientists deduced that the senior people may carry the immune memories from those induced by 1918H1N1-like flu viruses in their early years, which cross protected them from the H1N1 pdm09 virus attack [37]. However, the fact is that the 1918H1N1 virus also caused more deaths in younger people [38]. H7N9 and H5N1 viruses were limited in transmission due to the similar reason mentioned above with MERS-CoV and SARS-CoV. However, the mortality of H7N9 is as high as 37%, and H5N1 is 53% [39,40]. Nevertheless, the high pathogenicity and high mortality make them easier to be identified and controlled at the beginning of the break. Although H7N9 and H5N1 viruses transmitted in humans ineffectively, their geographic expansion and genetic recombination still suggested the potential of forming the next pandemic [41,42].

As listed in Table 1, people are easily infected with CoVs or IAVs through direct contact and airborne droplets [43]. Since most of these viruses are of animal origin or use animals as intermediate hosts [29,31], it is necessary to keep a safe distance between humans and wild animals, as well as maintaining ecological balance in the world to prevent the breaking of epidemics in future.

3. Clinical symptoms and diagnosis

The major clinical symptoms are summarized in Table 2. With the overview of the 8 viruses, the average incubation periods of the three HPCoVs are about 5 days or more, which are a little longer.
Fig. 1. Spike proteins and life cycles of CoV and IAV. 3D models of CoV with spike protein genes based polygenetic tree (A) and summary diagram of the CoV life cycle (B). (C) IAV with HA protein genes based polygenetic tree and (D) summary diagram of IAV life cycle. Both neighbor-joining trees are generated by using ClustalX 1.83 and MEGA7 with the full length of glycoprotein genes downloaded from GenBank. The year in the brackets indicates that the time of the virus was reported first.
than other viruses. At the early stage of disease onset, the cases with the infection of different viruses mostly developed the same clinical symptoms – cough and fever. However other clinical symptoms were various, such as myalgia which was common in HPCoVs, H1N1pdm09, and H3N2 IAV infection. Dyspnea was present in HPHTs infection, but not common in seasonal virus infections. Diarrhea was usually observed in patients with MERS and SARS, but not common in the other virus infections.

At the late stage of disease onset, compared with the seasonal viruses, all of the HPHTs can result in similar severe clinical symptoms, such as bilateral pneumonia, kidney damage, acute respiratory distress syndrome (ARDS), lactate dehydrogenase, and lymphocytopenia. In addition, three HPCoVs and H7N9 IAV infection usually showed ground glass pneumonia. MERS-CoV, SARS-CoV, H7N9 IAV, and H5N1 IAV caused more hepatic injury. SARS-CoV-2 and H5N1 IAV meanwhile caused more heart failure. The critical patient ratio of the HPHTs infection can be 10%–30% after 2–10 days of the disease development.

To detect the causative viruses, similar measures were applied for CoVs and IAVs. The specimen can be swabs, blood, or trachea extracts. Then the viral RNAs can be directly identified by reverse transcription polymerase chain reaction (RT-PCR) based methods, and the virus specific antibodies can be detected with enzyme-linked immunosorbent assay (ELISA) or related serological

| Table 1 | A summary of transmission of CoVs and IAVs. |
|---------|------------------------------------------|
| Viruses | First circulated | Transmitted by contact via | Susceptible | Infected people | Infected countries | Mortality | Intermediate host | References |
| Highly pathogenic or highly transmissible | | | | | | | | |
| SARS-CoV-2 2019 | Yes | NAΔ | Yes | Most were senior | Above 2 million by May 30 of 2020 | Global | About 7% by May 12 of 2020 | NA | [31,33,44,45] |
| MERS-CoV 2012 | Rarely | Yes | Yes | All ages | 2468 by November of 2019 | 9447 | 32 | 9% | Dromedary camel, bat | [15,32,34] |
| SARS-CoV 2003 | Yes | Yes | Yes | Most were younger | Above 200 million | Global | 0.001%–0.007% | Swine | [36,40] |
| H7N9 IAV 2013 | Rarely | Yes | Yes | Most were senior | 1568 by December of 2019 | Mainly in China | 37% | Avian | [42,47] |
| H1N1pdm09 2009 | Yes | Yes | Yes | Most were senior | Above 200 million | Global | 0.001%–0.007% | Swine | [36,40] |
| H5N1 IAV 1997 | Rarely | Yes | Yes | Most were younger | 861 (2003–2020) | 17 (2003–2020) | 53% | Avian | [41,49] |
| Seasonal HCoVsΔ | 1966 | Yes | Yes | Yes | All ages | up to 20% of cold cases | Global | NA | Bat, mice, cattle, palm civet | [14,28,52–54] |
| H3N2 IAV 1968 | Yes | Yes | NA | Most were senior | Global | NA | NA | Swine | [29,30,49,54] |

Δ HCoVs represents the four CoVs which caused common cold, HCoV229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1.  
Δ NA, data unavailable.

| Table 2 | Major clinical symptoms of the CoVs and IAVs. |
|---------|------------------------------------------|
| Viruses | Highly pathogenic or highly transmissible | Seasonal |
| | | HCoVs | H3N2 IAV |
| Incubation period (day) | Average 5.2 | Average 5.2 | Average 4.6 | Average 5 | 2 to 7 | 2 to 5 | 2 to 5 | NAΔ |
| Early stage of onset | Sore throat | + | ± | - | - | ± | + | ± | + |
| Cough | + | + | + | + | + | + | + | + | + |
| Fever | + | + | + | + | + | + | + | + | + |
| Myalgia | + | + | + | + | ± | + | ± | + | + |
| Dyspnea | + | + | + | + | + | ± | ± | ± | ± |
| Nausea and/or vomiting | ± | | 20%–35% | 20% | About 13% | 25% | About 13% | 25% | ± | ± |
| Diarrhea | ± | | | | | | | | |
| Later stage of onset | Bilateral pneumonia | + | + | + | + | ± | ± | ± | NA |
| Ground glass pneumonia | + | + | + | + | ± | ± | - | NA |
| Hepatic injury | ± | | + | + | ± | ± | - | NA |
| Kidney injury | + | + | + | + | ± | ± | - | NA |
| Heart failure | + | + | + | + | ± | ± | - | NA |
| ARDSε | + | + | + | + | ± | ± | - | NA |
| LDH increaseβ | + | + | + | + | + | ± | ± | - | NA |
| Lymphocytopenia | + | + | + | + | + | ± | ± | - | NA |
| Critical patient ratio (ICU) | 10.0–30.6% | 50% | 25% | >70% | 25% | 63% | 3.17% | 0.40% |
| References | [55–58] | [34,59–61] | [52,62–65] | [66–69] | [70–74] | [75–77] | [78–80] | [81–84] |

Δ ARDS, Acute respiratory distress syndrome.  
β LDH, Lactate dehydrogenase.  
ε + or –, uncommon or none.  
+ or –, common.  
± or –, some cases.  
NA, data unavailable.
methods. More detailed information has been summarized in the previous publication [13]. In order to deal with the simultaneous transmission of IAVs and CoVs, especially the new coronavirus, it is necessary to develop rapid and simple differential diagnosis technologies and methods for identification of IAVs and CoVs.

4. Pathological change

Both CoVs and IAVs can cause ARDS and lead to multiple organ failure and death. The published pathological data that were collected from autopsy, lung biopsies and chest computed tomography (CT) scan are summarized in Table 3. For patients with HPHTs infection, the general manifestations of the lung pathological change were inflammatory exudation or acute diffuse alveolar damage (DAD), with hyaline membrane formation, fibrin mucoid exudation, interstitial and alveolar edema, inflammatory interstitial infiltration and vascular congestion, epithelial cell proliferation, and pulmonary consolidation. However, there is no fibrin exudate found in the lungs of MERS patients, which may be related to the different stage of the disease progression. Almost all of the virus infections caused bronchioles injury except COVID-19 and H7N9 IAV [85,86], presented as the aggregation of fibrin in the bronchial intracavitary, the loss of cilia, the exfoliation of bronchioles epithelium, etc. It was reported that HCoVs were found to be associated with bronchiolitis in immunocompromised people, the elderly and young children, but showed light disease in the lungs.

5. Treatment

The RNA virus inhibitors were designed to target the different steps of virus replication cycle. Some of them inhibit virus entry or release, some interfere gene synthesis, and some inhibit virus protease, or some modulate innate immune response, like interferons etc. However, there are no specific drugs for treatment of CoVs infection. Most often used for treatment of SARS and MERS are ribavirin and lopinavir/ritonavir. Ribavirin is similar to guanosine and inosine and interfere viral RNA replication, which is more frequently used in combination with interferons to treat chronic hepatitis C infection [108]. Lopinavir and ritonavir are two protease inhibitors previously approved for HIV treatment, which usually used together and ritonavir as CYP3A4 inhibitor to enhance the activity of lopinavir [109].

The suitable medications for COVID-19 are still under search. So far, one of the most promising drugs is remdesivir (GS-5734), produced by Gilead Science, a nucleoside analog that mimics adenosine for previously treatment of the Ebola virus infection [110]. Health authorities in China have initiated clinical trials at multiple places in Hubei province to evaluate the safety and efficacy of remdesivir on patients. However, under the pandemic emergencies, the patients who recovered from critical situation usually took multiple medications rather than remdesivir, which made assessment of the data from clinical trials somewhat complicated [111]. Besides of China, Gilead Science started phase III trial. National Institute of Allergy and Infectious Diseases (NIAID) in the US are conducting phase II trial. The French National Institute of Health and Medical Research (INSERM) also evaluated the effect of remdesivir and other treatment on COVID-19 patients [112].

Another promising drug is chloroquine or its analog, hydroxychloroquine. It was reported that these two drugs may inhibit viral entry by affecting PH dependent endocytosis, and they may also affect viral glycosylation by inhibiting glycosyl-transferases [113]. They were approved to treat or prevent malaria, as well as rheumatoid arthritis, or systemic lupus erythematosus etc. Moreover, hydroxychloroquine showed fewer side effects than chloroquine [114]. Several clinical studies on hydroxychloroquine and chloroquine provided fairly satisfying results, better trial designing would be needed to further confirm the therapeutic effectiveness [115]. Besides of these medications, lopinavir/ritonavir, interferons, as well as the Chinese medicine formulate were also recommended by China for treatment of COVID-19 [116].

Currently, for clinical treatment of influenza infection, there are only three classes of FDA (Food and Drug Administration)-approved antiviral drugs available, including M2 ion channel inhibitors (amantadine and rimantadine), neuraminidase inhibitors (oseltamivir, zanamivir, peramivir and laninamivir), and the most recently RNA polymerase inhibitors (baloxavir marboxil) [117]. Amantadine and rimantadine can prevent the virus from shedding in the cytoplasm, thus inhibiting the transmission of virus offspring [118]. Although developed for many years, it has been reported frequently that they are ineffective in clinical treatment due to drug resistance of almost all currently circulating IAVs [119]. Furthermore, they have a relatively large side effect on the human central nervous system, thus are no longer recommended by WHO as the first choice of anti-influenza drugs for the treatment or prophylaxis of influenza [118].

Until now, the neuraminidase inhibitors (NAIs) are still the most ideal reagents for clinical treatment [120]. NAIs can prevent the hydrolytic activity of neuraminidase when the mature virus leaves the cell after budding, therefore stopping the virus from infecting healthy cells [121]. However, with heavy use in clinic, widespread oseltamivir-resistant H1N1 H275Y mutants have been identified [122]. According to a study carried out between 2008 and 2012 by WHO, oseltamivir resistance was found to be 2.9% (16/656 patients) [123], raising the alert that whether we can deal with influenza viruses once they break through the last line of defense? It has been found that probenecid can prevent the renal secretion of the parent compound of oseltamivir and significantly increase the blood concentration of oseltamivir [124]. Therefore the combination of oseltamivir and probenecid may be an important treatment option for severe patients.

Table 3
The pathological changes of the patients after infection.

| Viruses | Highly pathogenic or highly transmissible | Seasonal |
|---------|------------------------------------------|----------|
|         | SARS-CoV-2 | MERS-CoV | SARS-CoV | H7N9 IAV | H1N1 pdm09 | H5N1 IAV | HCoVs | H3N2 IAV |
| Diffuse alveolar damage | + | + | + | + | + | + | −<sup>c</sup> | NA<sup>a</sup> |
| Hyaline membrane | + | + | + | + | + | + | + | + |
| Fibromyxoid exudation | + | + | + | + | + | + | + | + |
| Pulmonary consolidation | + | + | + | + | + | + | + | + |
| Bronchiolitis | + | + | + | + | + | + | + | + |

<sup>a</sup> −, −−, common.
<sup>b</sup> −<sup>a</sup>, −−, uncommon or none.
<sup>c</sup> NA, data not available.

References [87–89], [90–93], [94,95], [96–98], [99–102], [103–106], [107].
Baloxavir marboxil, with a brand name of Xofloza, can target to viral polymerase acidic protein (PA), block its endonuclease function, leading to the inhibition of virus mRNA transcription and effectively prevent influenza A virus infection [125–127]. The antiviral spectrum of Xofloza includes seasonal influenza strains and influenza strains resistant to oseltamivir, significantly reducing the viral load compared with oseltamivir [128]. T-705 is a new type of RNA polymerase inhibitor which can inhibit a wide range of viruses by directly entering into the viral RNA chain or by binding directly to the viral RNA polymerase domain to block viral RNA chain replication and transcription [129,130]. It has been approved for listing in Japan [131,132].

With this in mind, it is quite urgent to develop novel anti-influenza drugs with higher antiviral potency and resistance barrier. Hemagglutinin glycoprotein, located on the surface of influenza virions [133], plays a critical role in virus attachment and membrane fusion. Accompanied with HA structure characteristics elucidated, HA inhibitors appear to be one of the most promising candidates [134–137]. With high efficacy and broad antiviral activity, some inhibitors targeting HA such as DAS181 and arbidol are currently in clinical development stage or partly approved for membrane fusion. Accompanied with HA structure characteristics binding to HA stem domain, which may be useful for the treatment of severe influenza disease [144].

6. Prevention

There are many types of vaccines that have been used or are under investigation for human viral disease, such as live attenuated virus vaccine, inactivated whole virus vaccine, subunit or recombinant vaccine, DNA plasmids based vaccine, and mRNA based vaccine. However, there are no available vaccines for prevention of CoV infection. More than 10 years of research on the development of vaccines against MERS-CoV and SARS-CoV indicated that S protein has the ability to induce neutralizing antibodies to stop virus infection [145,146], which shines light on SARS-CoV-2 vaccine study.

For development of SARS-CoV-2 vaccine, an intense global effort is currently underway [147]. So far several vaccines candidates have moved into clinical trials in China. One of them moved into phase II trial on April 12, which was produced by the Institute of Bioengineering, Academy of Military Medicine (NCT04341389) [148]. The research team led by Professor Chen took the modified replication defective adeno-virus as the vector, carried the S gene of the new CoV, to stimulate immune memory of S protein in humans. Their phase I trial was finished on March 27. In total 108 volunteers have completed the centralized medical observation without showing side effects (NCT04313127). In addition, LV-SMENP-DC, a dendritic cells vaccine, transduced with a lentivirus vector expression of several minigenes of SARS-CoV-2 and immunomodulatory genes, was developed by Shenzhen Geno-Immu Medical Institute (SGIMI) in China and used for injection of people along with activated virus antigen-specific cytotoxic T cells (NCT04276896). SGIMI also developed a second one using artificial antigen presenting cells (aAPCs) modified with lentivirus vector carrying similar genes with LV-SMENP-DC (NCT04295724). Two inactivated vaccines were approved for clinical trial as well, developed by the China National Pharmaceutical Group (Sinopharm) and Sinovac Research and Development Co., Ltd (NCT04352608) [147,149–152].

In addition to COVID-19 vaccine clinical trials in China, there are many SARS-CoV-2 vaccine clinical trials underway worldwide [153], such as a mRNA vaccine, mRNA-1273, produced by Moderna, Inc. in US (NCT04283461); a DNA vaccine, INO-4800 by Inovio, Inc. in US (NCT04336410); Bifidobacterium probiotic carrying S protein gene by Symvivo in Canada (NCT04334980); adenosivirus vaccine vector carrying S protein in UK (NCT04324606), etc. Whereas SARS-CoV-2 only started emerging in the human population, S protein, a major direct receptor interaction protein, and other viral proteins may continue modifying themselves to better adapt to humans [154]. Gene modification will bring more challenges into vaccine designing and development, especially the mutation in S protein which has been picked up by most of the vaccines candidates mentioned above.

Since the first H1N1 IAV vaccine was generated for prevention of the Spanish flu in 1938 by Jonas Salk and Thomas Francis [155,156], influenza vaccines have been improved dramatically. There are many types vaccines approved in US with trade names such as FluLaval, Fluarix, Agriflu, and Flublok. A live attenuated vaccine with the name of FluMist was approved by the Food and Drug Administration in US in 2003, and which is delivered through nasal spray [157]. To decrease side effects, animal and inactivated vaccines were also approved to replace chicken eggs as some growth of vaccine strain [158]. To provide protection from most seasonal virus attacks using one shot, multiple dominant viruses were included into one vaccine, such as those containing 3 or 4 different circulating strains and called trivalent or quadrivalent vaccines [158,159]. Before a universal vaccine was successfully developed, it is necessary to switch vaccines strains year by year as the prevalent influenza viruses mutate their genes or change their subtypes very frequently to escape from the immune recognition [24,29].

Up to now, available commercial vaccines against the IAVs those listed in this article are H1N1, H5N1 and H3N2 IAV vaccines, but not H7N9 flu vaccine. For example, a trivalent inactivated vaccine, TIV, produced by Seqirus Inc., usually has H1N1, H3N2 and B subtype viruses. FluMist, produced by MedImmune, Inc, is also used for H1N1 flu vaccine [158]. For H5N1 IAV, several inactivated vaccines are approved for human use, such as Audenz produced by Seqirus Inc [158], Prepardrix produced by GlaxoSmithKline Biologicals S.A [160]. H3N2 virus is usually a seasonal flu subtype in the last 30 years, of which the vaccine has been recommended for injection according to flu surveillance [29].

7. Summary

Human CoVs and IAVs share many characteristics, especially in HPHTs. Most of them infect the respiratory tract through direct contact and airway droplets and cause similar clinical symptoms like fever, cough, and sore throat. In contrast, MERS-CoV, H7N9 and H5N1 viruses rarely transmit between humans. SARS-CoV, H1N1 pdm09, and H5N1 viruses easily infect younger people. Severe patients usually infected with HPHTs develop bilateral pneumonia, ARDS, respiratory failure, and even death. CT and autopsy showed that the main pulmonary pathological manifestations were DAD, hyaline membrane formation, alveolar and interstitial edema, fibromyxoid exudation, etc. At present, there are no specific and effective drugs or vaccines for the treatment and prevention of CoVs. However, thanks to clinicians’ and scientists’ efforts worldwide, some promising progress has been made in the treatment of the diseases. Although there are some drugs and vaccines for the treatment and prevention of IAVs, it is still necessary to further research and develop more effective methods of treatment and prevention to better control the influenza epidemic.
Declaration of Competing Interest

The authors declare that they have no conflicts of interest.

Acknowledgements

Chungen Pan was supported by a grant from the Panu Inno- 
vation and Entrepreneurship Leading Team Project (2017-R02-2). 
Shuwen Liu was supported by Major scienti-
cation and Entrepreneurship Leading Team Project (2017-R02-4). 

References

[1] Pan X, Ojcius DM, Gao T, Li Z, Pan C, Pan C. Lessons learned from the 2019-
covid epidemic on prevention of future infectious diseases. Microbes Infect 2020;22:86–91.
[2] https://www.who.int/emergencies/diseases/novel-coronavirus-2019,
[3] Mahase E. Covid-19: outbreak could last until spring 2021 and see 7.9 million 
[4] patients coinfected with 2019 novel coronavirus and in 
[5] hospitalised in the UK. BMJ 2020;368:m1071.
[6] Khodamoradi Z, Moghadami M, Lot 
[7] Maier HJ, Bickerton E, Britton P. Preface. Coronaviruses. Methods Mol Biol 
[8] 2020;367.
[9] Saglanmak N, Andreasen V, Simonsen L, Molbak K, Miller MA, Viboud C. 
[10] Gradual changes in the age distribution of excess deaths in the years 
[11] following the 1918 influenza pandemic in Copenhagen: using epidemi-
[12] ological evidence to detect antigriffiant, drift, Vaccine 2011;29;Suppl 2;B42–84.
[13] Wu X, Xiao L, Li L. Research progress on human infection with avian inu-
[14] enza H7N9. Front Med 2020;14:8–20.
[15] Sun Y, Cao Y, Li Z, Bai T, Zhang H, Hu SX, et al. Cross-neutralizing anti-
[16] hemagglutinin antibodies isolated from patients infected with avian inu-
[17] a virus (H5N1). Biomed Environ Sci 2020;33:103–13.
[18] Imai M, Herfst S, Sorellt EM, Schrauwen EJ, De Graaf M, et al. Transmission of inu-
[19] enza A/H5N1 in fowl. Virus Res 2013;178:15–20.
[20] Tanner WD, Toth DJ, Gundlapalli AV. The pandemic potential of avian 
[21] enza A(H5N1) virus. Biomed Environ Sci 2020;33:103–13.
[22] Skowronski DM, Astell C, Brunham RC, Low DE, Petric M, Roper RL, et al. Characteris-
[23] tics of 245 cases of in 
[24] of pandemic (H1N1) 2009 in 
[25] to decade-long structural 
[26] of SARS coronavirus. J Virol 2020;94.
[27] Voorhies VL, Grant KA, Anderson HD, et al. Statistical analysis of pandemic (H1N1) 2009 in 
[28] 20;8495–902.
[29] Chua HX, Lim RL, Chen MC. Investigating the legacy of the 1918 influenza 
[30] pandemic in age-related seroepidemiology and immune responses to 
[31] subsequent inu 
[32] enza A viruses through a structural equation model. Am J Epidemiol 2018;187:2530–40.
[33] Saglanmak N, Andreasen V, Simonsen L, Molbak K, Miller MA, Viboud C. 
[34] Gradual changes in the age distribution of excess deaths in the years 
[35] following the 1918 influenza pandemic in Copenhagen: using epidemi-
[36] ological evidence to detect antigriffiant, drift, Vaccine 2011;29;Suppl 2;B42–84.
[37] Wu X, Xiao L, Li L. Research progress on human infection with avian inu-
[38] enza H7N9. Front Med 2020;14:8–20.
[39] Sun Y, Cao Y, Li Z, Bai T, Zhang H, Hu SX, et al. Cross-neutralizing anti-
[40] hemagglutinin antibodies isolated from patients infected with avian inu-
[41] a virus (H5N1). Biomed Environ Sci 2020;33:103–13.
[42] Imai M, Herfst S, Sorellt EM, Schrauwen EJ, De Graaf M, et al. Transmission of inu-
[43] enza A/H5N1 in fowl. Virus Res 2013;178:15–20.
[44] Tanner WD, Toth DJ, Gundlapalli AV. The pandemic potential of avian 
[45] enza A(H5N1) virus. Biomed Environ Sci 2020;33:103–13.
[46] Skowronski DM, Astell C, Brunham RC, Low DE, Petric M, Roper RL, et al. Characteris-
[47] tics of 245 cases of in 
[48] of pandemic (H1N1) 2009 in 
[49] to decade-long structural 
[50] of SARS coronavirus. J Virol 2020;94.
[51] Voorhies VL, Grant KA, Anderson HD, et al. Statistical analysis of pandemic (H1N1) 2009 in 
[52] 20;8495–902.
[53] Chua HX, Lim RL, Chen MC. Investigating the legacy of the 1918 influenza 
[54] pandemic in age-related seroepidemiology and immune responses to 
[55] subsequent inu 
[56] enza A viruses through a structural equation model. Am J Epidemiol 2018;187:2530–40.
[57] Saglanmak N, Andreasen V, Simonsen L, Molbak K, Miller MA, Viboud C. 
[58] Gradual changes in the age distribution of excess deaths in the years 
[59] following the 1918 influenza pandemic in Copenhagen: using epidemi-
[60] ological evidence to detect antigriffiant, drift, Vaccine 2011;29;Suppl 2;B42–84.
[61] Wu X, Xiao L, Li L. Research progress on human infection with avian inu-
[62] enza H7N9. Front Med 2020;14:8–20.
[63] Sun Y, Cao Y, Li Z, Bai T, Zhang H, Hu SX, et al. Cross-neutralizing anti-
[64] hemagglutinin antibodies isolated from patients infected with avian inu-
[65] a virus (H5N1). Biomed Environ Sci 2020;33:103–13.
[66] Imai M, Herfst S, Sorellt EM, Schrauwen EJ, De Graaf M, et al. Transmission of inu-
[67] enza A/H5N1 in fowl. Virus Res 2013;178:15–20.
[68] Tanner WD, Toth DJ, Gundlapalli AV. The pandemic potential of avian 
[69] enza A(H5N1) virus. Biomed Environ Sci 2020;33:103–13.
[70] Skowronski DM, Astell C, Brunham RC, Low DE, Petric M, Roper RL, et al. Characteris-
[71] tics of 245 cases of in 
[72] of pandemic (H1N1) 2009 in 
[73] to decade-long structural 
[74] of SARS coronavirus. J Virol 2020;94.
Kaji M, Watanabe A, Aizawa H. Differences in clinical features between influenza A H1N1, A H3N2, and B in adult patients. Respir Res 2003;8:28–33.

Zhang Z, Xia Y, Lu Y, Yang J, Zhang L, Su H, et al. Prediction of H7N9 epidemic in China. Chin Med J 2014;127:254–60.

Zhang S, Gu D, Ouyang X, Xie W. Proinflammatory effects of the hemagglutinin protein of the avian influenza A (H7N9) virus and microRNA-mediated homeostasis response in THP1 cells. Mol Med Rep 2015;12:6241–6.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420–2.

Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Respir Med 2020;8:2025–34.

Barton LM, Duval EJ, Strobeg E, Ghosh S, Mukhopadhyay S. COVID-19 autopsies, Oklahoma, USA. Am J Clin Pathol 2020;153:725–33.

Ng DL, Al Hosani F, Keating MK, Gerber SJ, Jones TL, Metcalfe MC, et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates. April 2014. Am J Pathol 2016;186:652–8.

Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003;361:1773–8.

Franks TJ, Chong PY, Chui P, Galvin JR, Lourens RM, Reid AH, et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Lancet 2003;361:1779–83.

Gu J, Geng E, Zhang B, Zheng J, Gao J, Zou Y, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med 2005;202:415–24.

Feng Y, Hu L, Lu S, Chen Q, Zheng Y, Zeng D, et al. Molecular pathology analyses of two fatal cases of avian infections of avian influenza A/H7N9 virus. J Clin Pathol 2015;68:57–63.

Wang Q, Zhang Z, Shi Y, Jiang Y. Emerging H7N9 influenza A (novel reasortiant avian) pneumonia: radiologic findings. Radiology 2013;288:882–9.

Bal A, Suri V, Mishra B, Bhalla A, Agarwal R, Abrol A, et al. Pathology and virology findings in cases of fatal influenza A H1N1 virus infection in 2009–2010. Histopathology 2012;60:326–35.

Masaoud T, Hajjar LA, Callegari GD, da Silva LF, Scortet D, Galas FR, et al. Lung pathology in fatal human influenza A (H1N1) infection. Am J Respir Crit Care Med 2010;181:72–9.

Bai L, Gu L, Cao B, Zhao XJ, Lu M, Yu L, et al. Clinical features of pneumonia caused by 2009 influenza A (H1N1) virus in Beijing, China. Chest 2011;139:1156–64.

Nakajima N, Van Tin N, Sato Y, Thach KN, Hatano K, Diep PH, et al. Pathologic study of archival lung tissues from five fatal cases of avian H5N1 influenza in Vietnam. Med Pathol 2013;26:357–69.

Korteweg C, Gu J. Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. Am J Pathol 2008;172:1153–70.

Uspiragertkul M, Kitphati R, Puthavathana P, Kiwong R, Kongsdangul A, Ungchusak K, et al. Apoptosis and pathogenesis of avian influenza A (H5N1) virus in humans. Emerg Infect Dis 2007;13:708–12.

Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Dick F, et al. Emergence of fatal human influenza A H1N1 subtype virus. Lancet 2008;372:637–41.

Woo PC, Lau SK, Toi HW, Huang Y, Poon RW, Chu CM, et al. Clinical and molecular epidemiological features of coronavirus HKU1-associated community-acquired pneumonia. J Infect Dis 2005;192:1898–907.

Valveret A, Mourier T, Gouarin S, Petitjean J, Freymuth F. An outbreak of coronavirus OC43 respiratory infection in Normandy, France. Clin Infect Dis 2003;36:985–9.

Pene F, Merlat A, Valveret A, Rozenberg F, Buzot D, Dreyfus F, et al. Coronavirus 229E-related pneumonia in immunocompromised patients. Clin Infect Dis 2003;37:929–32.

Ebihara T, Endo R, Ma X, Ishiguro N, Kikuta H. Detection of human coronaviruses in bronchial biopsies. J Med Virol 2005;75:463–8.

Guarnier J, Falcon-Escobedo R. Comparison of the pathology caused by H1N1, H5N1, and H3N2 influenza viruses. Arch Med Res 2009;40:655–61.

Hall CB, Ribavirin, Infect Dis News (N Y). 1985:4:73–5.

Dwyer J, Gross R, Kindrachuk J, Johnson RF, Olinger Jr GC, Hensley LE, et al. Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies. Drugs 2017;77:1935–55.
Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum antiviral drug targeting viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 2017;93:1044–1051.

Shen X, Zhang X, Liu S. Novel hemagglutinin-based influenza virus inhibitors. J Thorac Dis 2013;5:S149–59.

Saleemwine M, Satlin MJ, Hsu SE, Jenkins SG, Schuetz AN, Moss RB, et al. DAS181 for treatment of parainfluenza virus infections in hematopoietic stem cell transplant recipients at a single center. Biol Blood Marrow Transplant 2016;22:965–70.

Dhillon B, D’Souza A, Khajuria M, Saber W, Fenske TS, Moss RB, et al. DAS181 treatment of severe parainfluenza virus 3 pneumonia in allogeneic hematopoietic stem cell transplant recipients requiring mechanical ventilation. Case Rep Med 2016;2016:8503275.

Golombo RE, Fiorentino C, Dodd LE, Hunsberger S, Haney C, Barrett K, et al. A phase 1 randomized, double-blind, placebo-controlled, crossover trial of DAS181 (Fludase®) in adult subjects with well-controlled asthma. BMC Infect Dis 2016;16:54.

Liu DK, Bogdanova VS, Kirillov IM, Shchelkanov MY, Bertova EI, Bovin NV, et al. Evolution of pandemic influenza virus A(H1N1)pdm09 in 2009–2016: dynamics of receptor specificity of the first hemagglutinin subunit (HAI1). Vopr Virusol 2019;64:63–72.

Cueno ME, Inai K, Shimizu K, Ohai K. Homology modeling study toward identifying structural properties in the HA2 B-loop that would influence the H1 receptor-binding site. J Mol Graph Model 2013;44:161–7.

LVov DK, Bertova EI, Filipovic AG, Bogdanova VS, Shchelkanov MY, Bovin NV, et al. A possible association of fatal pneumonia with mutations of pandemic influenza A/H1N1 sw1 virus in the receptor-binding site of the H1 subunit. Vopr Virusol 2010;55:3–9.

Sutton TC, Lamardane EW, Bock KW, Moore IN, Koudstaal W, Rehman M, et al. In vitro sensitivity testing of oseltamivir is not predictive of prophylactic efficacy of broadly neutralizing monoclonal antibodies CR6261 and CR9114 against lethal H2 influenza virus challenge in mice. J Virol 2017;91.

Cao Z, Liu L, Du L, Zhang C, Jiang S, Li T, et al. Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol J 2010;7:299.

Wang N, Shang J, Jiang S, Du L. Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol 2020;11:298.

Chen WH, Strych U, Hotez PJ, Bottazzi ME. The SARS-CoV-2 vaccine pipeline: an overview. Curr Trop Med Rep 2020;7:1–4.

Zhang J, Zeng H, Gu J, Li H, Zheng L, Zhou Q. Progress and prospects on vaccine development against SARS-CoV-2. Vaccines (basel) 2020;8:20.

Wang F, Kream RM, Stefano GB. An evidence based perspective on mRNA-SARS-CoV-2 vaccine development. Med Sci Mon Int Med J Exp Clin Res 2020;26:e924700.

Pawelec G, Weng NP. Can an effective SARS-CoV-2 vaccine be developed for the older population? Immun Ageing 2020:17:8.

Bhattacharya M, Sharma AR, Patra P, Ghosh P, Sharma G, Patra BC, et al. Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-CoV-2): immunoinformatics approach. J Med Virol 2020;92:

Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 2020;12:1.

Tu YF, Chien CS, Yarmishyn AA, Lin YY, Luo YH, Lin YT, et al. A review of SARS-CoV-2 and the ongoing clinical trials. Int J Mol Sci 2020;21:7.

Yin C. Genotyping coronavirus SARS-CoV-2: methods and implications. Genomics 2020. https://doi.org/10.1016/j.ygeno.2020.04.016 [online ahead of print].

Francis ME, Meenai M, Dawe NJ, Foley MK, King ML, Ross TM, et al. Historical H1N1 influenza virus imprinting increases vaccine protection by influencing the activity and sustained production of antibodies elicited at vaccination in ferrets. Vaccines (basel), vol. 7; 2019.

Huang F, Yu S, Wu C, Liang L. Highly conserved antigenic epitope regions of hemagglutinin and neuraminidase genes between 2009 H1N1 and seasonal H1N1 influenza: vaccine considerations. J Transl Med 2013;11:47.

Schaefer S, Simon M. FluMist: reconsidering the contraindications. Clin Pediatr (Phila) 2015;54:1021.

McDonald J, Moore D. FluMist vaccine: questions and answers - summary. Paediatr Child Health 2011;16:31.

Groshkopf LA, Sokolow LZ, Broder KR, Walter EB, Bresee JS, Fry AM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices - United States, 2017–18 influenza season. MMWR Recomm Rep (Morb Mortal Wkly Rep) 2017;66:1–20.

Carter NJ, Ploeger GL. Preparident influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus. BioDrugs 2008;22:279–92.